Ormutivimab

• Description :

  Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model[1][2].

• CAS Number :

  [2449086-91-1]

• Product Name Alternative :

  NM57; rhRIG

• UNSPSC :

  12352203

• Target :

  RABV

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/ormutivimab.html

• Solubility :

  10 mM in DMSO

• Smiles :

  [Ormutivimab]

• References & Citations :

  [1]Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267. |[2]Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel) . 2022 Jul 29;10 (8) :1218.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported